MGX logo

Metagenomi Common Stock (MGX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

06 April 2006

Indexes:

Not included

Description:

MGX (Metagenomi) focuses on gene editing technologies to develop innovative therapies for genetic diseases. The company uses advanced tools to modify genes, aiming to improve health outcomes and create new treatment options. Their work combines biotechnology and medicine to address unmet medical needs.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

10 Dec '24 HC Wainwright & Co.
Buy
21 Nov '24 HC Wainwright & Co.
Buy
20 Nov '24 Chardan Capital
Buy
15 Oct '24 HC Wainwright & Co.
Buy
06 Sept '24 HC Wainwright & Co.
Buy
05 Sept '24 Chardan Capital
Buy
21 Aug '24 HC Wainwright & Co.
Buy
19 Aug '24 Chardan Capital
Buy
15 Aug '24 BMO Capital
Outperform
15 July '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Metagenomi, Inc. Class Action: Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024 - MGX
Metagenomi, Inc. Class Action: Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024 - MGX
Metagenomi, Inc. Class Action: Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024 - MGX
MGX
accesswire.com25 November 2024

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113560&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Metagenomi, Inc. (MGX) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Metagenomi, Inc. (MGX) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Metagenomi, Inc. (MGX) Shareholders
MGX
accesswire.com25 November 2024

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113547&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. - MGX
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. - MGX
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. - MGX
MGX
prnewswire.com25 November 2024

NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

MGX LAWSUIT ALERT: Levi & Korsinsky Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
MGX LAWSUIT ALERT: Levi & Korsinsky Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
MGX LAWSUIT ALERT: Levi & Korsinsky Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
MGX
accesswire.com25 November 2024

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113528&wire=1 or contact Joseph E. Levi, Esq.

Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX
Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX
Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX
MGX
accesswire.com25 November 2024

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113509&wire=1 or contact Joseph E. Levi, Esq.

Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Metagenomi, Inc. Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm
MGX
accesswire.com25 November 2024

LOS ANGELES, CA / ACCESSWIRE / November 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Metagenomi, Inc. ("Metagenomi" or "the Company") (NASDAQ:MGX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about February 9, 2024, are encouraged to contact the firm before November 25, 2024.

MGX DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX
MGX DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX
MGX DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important November 25 Deadline in Securities Class Action – MGX
MGX
globenewswire.com25 November 2024

NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline.

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGX
Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGX
Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGX
MGX
accesswire.com25 November 2024

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113468&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
MGX
accesswire.com24 November 2024

NEW YORK, NY / ACCESSWIRE / November 24, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113336&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by November 25, 2024 Deadline to Join Class Action Against Metagenomi, Inc.(MGX)
Contact Levi & Korsinsky by November 25, 2024 Deadline to Join Class Action Against Metagenomi, Inc.(MGX)
Contact Levi & Korsinsky by November 25, 2024 Deadline to Join Class Action Against Metagenomi, Inc.(MGX)
MGX
accesswire.com24 November 2024

NEW YORK, NY / ACCESSWIRE / November 24, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=113328&wire=1 or contact Joseph E. Levi, Esq.

FAQ

  • What is the primary business of Metagenomi Common Stock?
  • What is the ticker symbol for Metagenomi Common Stock?
  • Does Metagenomi Common Stock pay dividends?
  • What sector is Metagenomi Common Stock in?
  • What industry is Metagenomi Common Stock in?
  • What country is Metagenomi Common Stock based in?
  • When did Metagenomi Common Stock go public?
  • Is Metagenomi Common Stock in the S&P 500?
  • Is Metagenomi Common Stock in the NASDAQ 100?
  • Is Metagenomi Common Stock in the Dow Jones?
  • When was Metagenomi Common Stock's last earnings report?
  • When does Metagenomi Common Stock report earnings?
  • Should I buy Metagenomi Common Stock stock now?

What is the primary business of Metagenomi Common Stock?

MGX (Metagenomi) focuses on gene editing technologies to develop innovative therapies for genetic diseases. The company uses advanced tools to modify genes, aiming to improve health outcomes and create new treatment options. Their work combines biotechnology and medicine to address unmet medical needs.

What is the ticker symbol for Metagenomi Common Stock?

The ticker symbol for Metagenomi Common Stock is NASDAQ:MGX

Does Metagenomi Common Stock pay dividends?

No, Metagenomi Common Stock does not pay dividends

What sector is Metagenomi Common Stock in?

Metagenomi Common Stock is in the Healthcare sector

What industry is Metagenomi Common Stock in?

Metagenomi Common Stock is in the Biotechnology industry

What country is Metagenomi Common Stock based in?

Metagenomi Common Stock is headquartered in United States

When did Metagenomi Common Stock go public?

Metagenomi Common Stock's initial public offering (IPO) was on 06 April 2006

Is Metagenomi Common Stock in the S&P 500?

No, Metagenomi Common Stock is not included in the S&P 500 index

Is Metagenomi Common Stock in the NASDAQ 100?

No, Metagenomi Common Stock is not included in the NASDAQ 100 index

Is Metagenomi Common Stock in the Dow Jones?

No, Metagenomi Common Stock is not included in the Dow Jones index

When was Metagenomi Common Stock's last earnings report?

Metagenomi Common Stock's most recent earnings report was on 13 November 2024

When does Metagenomi Common Stock report earnings?

The next expected earnings date for Metagenomi Common Stock is 28 February 2025

Should I buy Metagenomi Common Stock stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions